Abbott Gets FDA Approval for AI-Powered Imaging Tech
August 03 2021 - 9:33AM
Dow Jones News
By Matt Grossman
Abbott Laboratories has gotten an approval from the U.S. Food
and Drug Administration for imaging software that uses artificial
intelligence to visualize coronary blood flow and blockages.
The Abbott Park, Ill.-based medical-device maker had already
received European approval for the technology, an optical coherence
tomography imaging platform using Abbott's Ultreon software.
The technology can help doctors improve treatment plans, Abbott
said. "As cardiologists continue to adopt OCT and move away from
traditional imaging methods such as angiography, emerging
technologies are pivotal to determine the best course of patient
care," said Dr. Nick West, Abbott's chief medical officer for its
vascular business.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
August 03, 2021 09:27 ET (13:27 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Apr 2023 to Apr 2024